A股異動 | 聖湘生物漲7% 相關產品取得醫療器械註冊證及法國衞生部備案許可
格隆匯1月7日丨聖湘生物(002988.SZ)現漲7.8%,報64.11元,總市值256億元。聖湘生物今日發佈公吿,公司產品人乳頭瘤病毒核酸檢測試劑盒(PCR-熒光探針法)於近日收到由國家藥品監督管理局頒發的《醫療器械註冊證》,新型冠狀病毒(SARS-CoV-2)L452R/E484K/K417N突變核酸檢測試劑盒(熒光PCR法)(英文名稱SARS-CoV-2 L452R/E484K/K417N Mutation Nucleic Acid Detection Kit(PCR-Fluorescence Probing))於近日獲得法國衞生部的備案許可。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.